Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From Canaccord
https://ibb.co/5KPtkc2
Totally agree on that!!! LABS will survive and prosper
Which will be worth more in 6 months? $LABS or your $ACB. Mark your calendar
Unless some news from LABS expect the sector to be down and more buying opportunities
Thanks! Good luck this week to all us Med Heads here. Been a rough red few weeks we deserve some green. : )
Or be broke, lol! My timeframe is years with LABS, so collecting at this cheap price so my core is large enough to sell some on large spikes... fingers crossed of course
Added 4K shares more at $1.89 usd see what this week brings, saved powder in case
This is from the last conference call and is even more applicable now that companies like Aurora are having to accept returns of unsold inventory. The oversupply of cannabis has given Medipharm the ability to pick and choose the quality of what they receive and at much better pricing. Given the very limited extractors in the business, I would think Medipharm will be sitting pretty in the upcoming earnings release. Think about it...did Heinz ketchup ever go out of business because there were too many tomato farmers? Nope. The producers will come and go. It's the final product that people want:
" Although, we're optimistic that we will start seeing a more steady supply of organic biomass come online, the overall industry supply of dry cannabis inventory has hit record highs. This bodes extremely well for MediPharm. At these levels, we've been able to secure significant volumes of high quality and high active component biomass at more attractive pricing, ensuring we can fulfill all of our contacts to-date ability for 2.0.
We expect to see this trend continue, which will only further support our margins moving forward as we acquire only the best yielding dry cannabis, establishing a reliable supply chain for domestic and international products.".
https://www.google.com/amp/s/seekingalpha.com/amp/article/4305751-medipharm-labs-corp-medif-ceo-pat-mccutcheon-on-q3-2019-results-earnings-call-transcript
Well neither you or I called this new low for your $ACB unfortunately! But $LABS hit your low. You still in $ACB HIPPD????
lol, I hear you! If only.....
Eventually we will care and be noticed, big VALENS fan but they are dependent on Canada market we are expanding internationally. Look at the sp of both....hmmm
https://www.google.com/amp/s/potstocknews.com/3-pot-stocks-german-cannabis-market/amp/
CAPITULATION!!
I’m going down with the ship GLTA
Nope, none! The “unknown “ where people ASSUMED it to be $ACB, turned out to be the turd named HEXO
Nice move, with swapping nept for labs
Canadian or US dollars?
Shorts own the extractors, damn shame
Anybody add today or still expensive.....
Coming up:
https://ibb.co/J2BHJx7
Ouch:
Elixinol Global Abandons Australian Businesses to Focus on CBD and Will Absorb A$17.8 Million in Write-Downs
I’ll be here 2 yrs from now
Big news!!!
Not sure where bottom is? Patience is gonna have to do here if you believe in your dd
Yep, GL LONGS!!!
MediPharm Labs Reaffirms Focus on Global Growth with Strong Aggregate Liquidity; Increases Cannabis 2.0 Shipments
BARRIE, Ontario, Jan. 30, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven, pharmaceutical quality cannabis extraction, distillation, and derivative products, today provided an update on its aggregate liquidity position, which supports plans for domestic and international growth, and announced it has fulfilled further Cannabis 2.0 product shipments to Canadian provincial distributors in January 2020.
The Company continues to maintain a very strong balance sheet and had an unaudited aggregate liquidity position of approximately $67 million as at December 31, 2019.
“With our strong balance sheet, a healthy aggregate liquidity position, supply of pharmaceutical-quality products and the fact that the Cannabis 2.0 market is opening, we are well positioned to support our customers in Canada as they ramp up sales, as well as new potential customers in emerging international markets,” said Pat McCutcheon, CEO, MediPharm Labs. “In Canada, as the consumer market begins to achieve its full potential, we have remained disciplined in shaping our committed wholesale and service agreements based on our credit policies and sizeable upfront payments.”
As noted in the Company’s press release dated January 24, 2020, the Company filed a statement of claim against one of its customers after negotiations to settle a past due amount proved unsuccessful. To provide additional background, the Company considers this claim to be a singular event and not representative of the strong liquidity of its customer base. As at December 31, 2019, the Company’s unaudited past due balance was approximately $8.6 million, of which $7.7 million was related to the statement of claim. The majority of the other remaining outstanding balance has already been collected as of today. The Company is pleased to note that it expects to collect its existing receivables in the normal course of business and does not perceive any additional credit risk on its remaining customer base due to the high credit worthiness of these customers.
Increasing Cannabis 2.0 Shipments
In late December 2019, the Company commenced shipments of Cannabis 2.0 products into three of Canada’s provincial jurisdictions - British Columbia, Manitoba and Saskatchewan. Following initial shipments in December, the Company received multiple purchase re-orders. Because of the nature of its business, MediPharm Labs is also able to supply B2B customers serving four product categories recognized under Schedule 4 of the Cannabis Act: cannabis extracts (for ingestion and Inhalation), cannabis topicals, edible cannabis (beverages and food products) and cannabis oils. This exposure to each cannabis 2.0 product category is another element of the Company’s risk-managed plan for diversifying its growth – the primary elements being international expansion and focus on the global medical market.
“As the Canadian market builds on the launch of the next generation of cannabis products, our specialized GMP certified platform and ability to produce a stable supply of pharmaceutical-quality concentrates will continue to position us to support various licensed producers and new upcoming direct to consumer brands launching innovative products,” said Pat McCutcheon, CEO, MediPharm Labs. “Beginning last year, in anticipation of a slower rollout of Cannabis 2.0 products in Canada, we made the decision to accelerate our international diversification plans and develop our capabilities to partner with international pharmaceutical companies to address an emerging medical cannabis consumer and research market.”
Enactment of Cannabis 2.0 federally, and recent moves by the Ontario government to accelerate licence applications from prospective retailers in Canada’s largest province are expected to improve product choice and accessibility for consumers as the retail market matures.
People are getting same email, but it’s a full go I feel. See below
https://ibb.co/ZcVNDLW
A few smart ones here
Read the whole thing
https://ibb.co/hK0YJRQ
I added a few... I’ll wait it out GL to longs
Interesting:
https://ibb.co/z8dvkCK
From a reliable source this is the only financial issue with LABS. Not of their fault either. This was a direct contact made Friday night by phone to LABS. No B.S., why I bought more and in real heavy, be broke or rich in 5 yrs lol
They didn’t pick HEXO, LABS did contract with NEWSTRIKE, HEXO bought out them and thus their contract with us.
I don’t know about that, but time will tell too late now
Added to both labs & vlns today, down but in for long run
Betting Bruiser (@BettingBruiser)
1/27/20, 5:11 PM
To put it simply $HEXO is in breach of contract $LABS #PotStocks pic.twitter.com/Kg2kQnOcMg
You still holding long here? And all extractors just wondering
HEXO not paying us
Thnx stack